| Intrinsic Bioprobes Launches Three New CLIA Approved Mass Spectrometry-Based ... - PR Newswire (press release) |
|
|
PR Newswire (press release) The three target proteins - beta-2-microglobulin, cystatin C, and retinol binding protein - are FDA approved clinical markers for in-vitro diagnosis of kidney disease and renal failure. However, all three proteins exhibit structural microheterogeneity |